Literature DB >> 6112327

Hepatoerythropoietic porphyria: a new uroporphyrinogen decarboxylase defect or homozygous porphyria cutanea tarda?

G H Elder, S G Smith, C Herrero, M Lecha, J M Mascaro, A M Muniesa, D B Czarnecki, J Brenan, V Poulos, R E DE Salamanca.   

Abstract

Uroporphyrinogen decarboxylase levels were measured in haemolysed whole blood or fibroblasts from 3 unrelated patients with hepatoerythropoietic porphyria (HEP) and in 4 unrelated patients with familial porphyria cutanea tarda, a condition in which the enzyme is defective. In HEP patients enzyme activities were 7% of normal in erythrocytes and 8% of normal in cultured skin fibroblasts. All the features of HEP, including the characteristic accumulation of protoporphyrin in erythrocytes, are secondary to this enzyme defect. The father of 1 HEP patient was heterozygous for the same enzyme defect. He also had uroporphyrinuria and was therefore indistinguishable from patients with subclinical familial porphyria cutanea tarda. It is suggested that patients with HEP are homozygous for the gene that causes porphyria cutanea tarda.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6112327     DOI: 10.1016/s0140-6736(81)91615-9

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  12 in total

1.  Steady-state levels of uroporphyrinogen decarboxylase mRNA in lymphoblastoid cell lines from patients with familial porphyria cutanea tarda and their relatives.

Authors:  J L Hansen; M A Pryor; J B Kennedy; J P Kushner
Journal:  Am J Hum Genet       Date:  1988-06       Impact factor: 11.025

2.  Homozygous variegate porphyria: two similar cases in unrelated families.

Authors:  G M Murphy; J L Hawk; I A Magnus; D F Barrett; G H Elder; S G Smith
Journal:  J R Soc Med       Date:  1986-06       Impact factor: 5.344

3.  Hepatoerythropoietic porphyria due to a novel mutation in the uroporphyrinogen decarboxylase gene.

Authors:  J To-Figueras; J D Phillips; J M Gonzalez-López; C Badenas; I Madrigal; E M González-Romarís; C Ramos; J M Aguirre; C Herrero
Journal:  Br J Dermatol       Date:  2011-08-18       Impact factor: 9.302

4.  Characterization of a new mutation (R292G) and a deletion at the human uroporphyrinogen decarboxylase locus in two patients with hepatoerythropoietic porphyria.

Authors:  H de Verneuil; F Bourgeois; F de Rooij; P D Siersema; J H Wilson; B Grandchamp; Y Nordmann
Journal:  Hum Genet       Date:  1992-07       Impact factor: 4.132

Review 5.  Porphyria Diagnostics-Part 1: A Brief Overview of the Porphyrias.

Authors:  Vaithamanithi-Mudumbai Sadagopa Ramanujam; Karl Elmo Anderson
Journal:  Curr Protoc Hum Genet       Date:  2015-07-01

6.  Enzymatic and immunological studies of uroporphyrinogen decarboxylase in familial porphyria cutanea tarda and hepatoerythropoietic porphyria.

Authors:  H de Verneuil; C Beaumont; J C Deybach; Y Nordmann; Z Sfar; R Kastally
Journal:  Am J Hum Genet       Date:  1984-05       Impact factor: 11.025

7.  Isolation and identification of a cDNA clone coding for rat uroporphyrinogen decarboxylase.

Authors:  P H Romeo; A Dubart; B Grandchamp; H de Verneuil; J Rosa; Y Nordmann; M Goossens
Journal:  Proc Natl Acad Sci U S A       Date:  1984-06       Impact factor: 11.205

8.  Purification of uroporphyrinogen decarboxylase from human erythrocytes. Immunochemical evidence for a single protein with decarboxylase activity in human erythrocytes and liver.

Authors:  G H Elder; J A Tovey; D M Sheppard
Journal:  Biochem J       Date:  1983-10-01       Impact factor: 3.857

9.  Prevalence of the 281 (Gly----Glu) mutation in hepatoerythropoietic porphyria and porphyria cutanea tarda.

Authors:  H de Verneuil; J Hansen; C Picat; B Grandchamp; J Kushner; A Roberts; G Elder; Y Nordmann
Journal:  Hum Genet       Date:  1988-01       Impact factor: 4.132

10.  Molecular analysis of uroporphyrinogen decarboxylase deficiency in a family with two cases of hepatoerythropoietic porphyria.

Authors:  H de Verneuil; B Grandchamp; P H Romeo; N Raich; C Beaumont; M Goossens; H Nicolas; Y Nordmann
Journal:  J Clin Invest       Date:  1986-02       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.